A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma

NCT ID: NCT06742996

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-05

Study Completion Date

2032-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mantle Cell Lymphoma B Cell Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

mantle cell lymphoma MCL relapsed/refractory mantle cell lymphoma sonrotoclax

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: sonrotoclax plus zanubrutinib

Sonrotoclax and zanubrutinib will be administered in combination.

Group Type EXPERIMENTAL

Sonrotoclax

Intervention Type DRUG

Administered orally

Zanubrutinib

Intervention Type DRUG

Administered orally

Arm B: placebo plus zanubrutinib

Placebo and zanubrutinib will be administered in combination.

Group Type PLACEBO_COMPARATOR

Zanubrutinib

Intervention Type DRUG

Administered orally

Placebo

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sonrotoclax

Administered orally

Intervention Type DRUG

Zanubrutinib

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BGB-11417 Brukinsa BGB-3111

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC)
* Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator
* Relapsed or refractory disease after the last line of therapy
* Measurable disease defined as ≥ 1 nodal lesion that is \> 1.5 cm in longest diameter, or ≥ 1 extranodal lesion that is \> 1 cm in longest diameter
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
* Adequate organ function

Exclusion Criteria

* Prior therapy with B-cell lymphoma-2 inhibitor
* Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi
* Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
* Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug
* Known central nervous system involvement by lymphoma
* Clinically significant cardiovascular disease
* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BeiGene

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

BeiGene

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Santa Rita de Cassia Afecc

Vitória, , Brazil

Site Status RECRUITING

University of Alabama At Birmingham Hospital

Birmingham, Alabama, United States

Site Status RECRUITING

Mayo Clinic Phoenix

Phoenix, Arizona, United States

Site Status RECRUITING

Yale University, Yale Cancer Center

New Haven, Connecticut, United States

Site Status RECRUITING

Memorial Cancer Institute, Memorial Healthcare System

Pembroke Pines, Florida, United States

Site Status RECRUITING

Cleveland Clinic Florida

Weston, Florida, United States

Site Status RECRUITING

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, United States

Site Status RECRUITING

Mission Cancer and Blood

Waukee, Iowa, United States

Site Status RECRUITING

University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States

Site Status RECRUITING

Dana Farber Cancer Institute Longwood Medical Center

Boston, Massachusetts, United States

Site Status RECRUITING

University of Michigan

Ann Arbor, Michigan, United States

Site Status RECRUITING

The Cancer and Hematology Centers

Grand Rapids, Michigan, United States

Site Status RECRUITING

Mayo Clinic Rochester

Rochester, Minnesota, United States

Site Status RECRUITING

Hattiesburg Hematology and Oncology Clinic

Hattiesburg, Mississippi, United States

Site Status RECRUITING

Washington University School of Medicine

St Louis, Missouri, United States

Site Status RECRUITING

Nebraska Cancer Specialists St Francis Grand Island

Grand Island, Nebraska, United States

Site Status RECRUITING

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Site Status RECRUITING

The Valley Hospital, Inc

Paramus, New Jersey, United States

Site Status RECRUITING

Atrium Health Levine Cancer Institute (Lci)

Charlotte, North Carolina, United States

Site Status RECRUITING

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina, United States

Site Status RECRUITING

University Hospitals

Cleveland, Ohio, United States

Site Status RECRUITING

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status RECRUITING

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Site Status RECRUITING

Ohio Health Research Institute

Columbus, Ohio, United States

Site Status RECRUITING

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status RECRUITING

McGlinn Cancer Institute

West Reading, Pennsylvania, United States

Site Status RECRUITING

Tennesse Oncology Chattanooga Downtown

Chattanooga, Tennessee, United States

Site Status RECRUITING

Tennessee Oncology

Nashville, Tennessee, United States

Site Status RECRUITING

Md Anderson Cancer Center

Houston, Texas, United States

Site Status RECRUITING

Texas Oncology Austin Midtown

Round Rock, Texas, United States

Site Status RECRUITING

University of Virginia

Charlottesville, Virginia, United States

Site Status RECRUITING

Virgina Cancer Specialists

Gainesville, Virginia, United States

Site Status RECRUITING

Vcu Massey Cancer Center

Richmond, Virginia, United States

Site Status RECRUITING

Northwest Cancer Specialist, Pc(Us Oncology Research)

Vancouver, Washington, United States

Site Status RECRUITING

Hospital Aleman

CABA, , Argentina

Site Status RECRUITING

Hospital Italiano de Buenos Aires

Ciudad Autonoma Buenos Aires, , Argentina

Site Status RECRUITING

Concord Repatriation General Hospital

Concord, New South Wales, Australia

Site Status RECRUITING

Genesiscare North Shore

St Leonards, New South Wales, Australia

Site Status RECRUITING

Westmead Hospital

Westmead, New South Wales, Australia

Site Status RECRUITING

Sunshine Coast Hospital and Health Service

Birtinya, Queensland, Australia

Site Status RECRUITING

Box Hill Hospital

Box Hill, Victoria, Australia

Site Status RECRUITING

Monash Health

Clayton, Victoria, Australia

Site Status RECRUITING

Rockingham Hospital

Cooloongup, Western Australia, Australia

Site Status RECRUITING

Linear Clinical Research

Nedlands, Western Australia, Australia

Site Status RECRUITING

One Clinical Research

Nedlands, Western Australia, Australia

Site Status RECRUITING

Perth Blood Institute

West Perth, Western Australia, Australia

Site Status RECRUITING

Ordensklinikum Linz Gmbh Elisabethinen

Linz, , Austria

Site Status RECRUITING

Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg

Salzburg, , Austria

Site Status RECRUITING

Uk St Poelten

Sankt Pölten, , Austria

Site Status RECRUITING

Fundacao Pio Xii Hospital de Amor de Barretos

Barretos, , Brazil

Site Status RECRUITING

Hospital Felicio Rocho

Belo Horizonte, , Brazil

Site Status RECRUITING

Universidade de Campinas Centro de Hematologia E Hemoterapia

Campinas, , Brazil

Site Status RECRUITING

Hospital Erasto Gaertner

Curitiba, , Brazil

Site Status RECRUITING

Instituto Joinvilense de Hematologia E Oncologia

Joinville, , Brazil

Site Status RECRUITING

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude

Petrópolis, , Brazil

Site Status RECRUITING

Hospital de Clinicas de Porto Alegre

Porto AlegreRS, , Brazil

Site Status RECRUITING

Hospital Do Cancer de Pernambuco

Recife, , Brazil

Site Status RECRUITING

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Beijing Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular

São Paulo, , Brazil

Site Status RECRUITING

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Site Status RECRUITING

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Site Status RECRUITING

Sun Yat Sen University Cancer Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status RECRUITING

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Site Status RECRUITING

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Site Status RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status RECRUITING

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status RECRUITING

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Site Status RECRUITING

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Site Status RECRUITING

Jiangxi Province Cancer Hospital

Nanchang, Jiangxi, China

Site Status RECRUITING

Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, China

Site Status RECRUITING

Shaanxi Provincial Peoples Hospital

Xi'an, Shaanxi, China

Site Status RECRUITING

Linyi Cancer Hospital

Linyi, Shandong, China

Site Status RECRUITING

The Affiliated Hospital of Qingdao University Branch West Coast

Qingdao, Shandong, China

Site Status RECRUITING

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

Chengdu, Sichuan, China

Site Status RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan

Hangzhou, Zhejiang, China

Site Status RECRUITING

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Site Status RECRUITING

Chu Montpellier Hopital Saint Eloi

Montpellier, , France

Site Status RECRUITING

Centre Hospitalier Universitaire Nantes Hotel Dieu

Nantes, , France

Site Status RECRUITING

Chu Hopital Lyon Sud

PierreBenite, , France

Site Status RECRUITING

Chu Tours Hopital Bretonneau

Tours, , France

Site Status RECRUITING

Klinikum Chemnitz Ggmbh

Chemnitz, , Germany

Site Status RECRUITING

Stauferklinikum Schwabisch Gmund Kliniken Ostalb

Mutlangen, , Germany

Site Status RECRUITING

Policlinico Sorsola Malpighi, Aou Di Bologna

Bologna, , Italy

Site Status RECRUITING

Ospedale Vito Fazzi, Asl Lecce

Leece, , Italy

Site Status RECRUITING

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst

Meldola, , Italy

Site Status RECRUITING

Azienda Sanitaria Universitaria Giuliano Isontina

Trieste, , Italy

Site Status RECRUITING

Centroricerche Cliniche Di Verona Srl

Verona, , Italy

Site Status RECRUITING

Aichi Cancer Center Hospital Clinical Oncology

Nagoya, Aichi-ken, Japan

Site Status RECRUITING

Toyohashi Municipal Hospital

Toyohashishi, Aichi-ken, Japan

Site Status RECRUITING

Chiba Cancer Center

Chiba, Chiba, Japan

Site Status RECRUITING

Matsuyama Red Cross Hospital

Matsuyama, Ehime, Japan

Site Status RECRUITING

Ogaki Municipal Hospital

Ōgaki, Gifu, Japan

Site Status RECRUITING

Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital

Hiroshima, Hiroshima, Japan

Site Status RECRUITING

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

Site Status RECRUITING

Kobe City Medical Center General Hospital

KobeShi, Hyōgo, Japan

Site Status RECRUITING

Kagoshima University Hospital

Kagoshima, Kagoshima-ken, Japan

Site Status RECRUITING

Kanagawa Cancer Center

Yokohama, Kanagawa, Japan

Site Status RECRUITING

Tohoku University Hospital

Sendai, Miyagi, Japan

Site Status RECRUITING

Kurashiki Central Hospital

Kurashikishi, Okayama-ken, Japan

Site Status RECRUITING

Osaka Red Cross Hospital

Osakashi, Osaka, Japan

Site Status RECRUITING

Dokkyo Medical University Saitama Medical Center

Koshigaya, Saitama, Japan

Site Status RECRUITING

National Hospital Organization Okayama Medical Center

Okayama, , Japan

Site Status RECRUITING

Osaka Metropolitan University Hospital

Osaka, , Japan

Site Status RECRUITING

Institute of Science Tokyo Hospital

Tokyo, , Japan

Site Status RECRUITING

Yokohama Municipal Citizens Hospital

Yokohama, , Japan

Site Status RECRUITING

North Shore Hospital

Auckland, , New Zealand

Site Status RECRUITING

Christchurch Hospital

Christchurch, , New Zealand

Site Status RECRUITING

Dunedin Hospital

Dunedin, , New Zealand

Site Status RECRUITING

Tauranga Hospital

Tauranga, , New Zealand

Site Status RECRUITING

Wellington Regional Hospital (Ccdhb)

Wellington, , New Zealand

Site Status RECRUITING

Pratia McM Krakow

Krakow, , Poland

Site Status RECRUITING

Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi

Lodz, , Poland

Site Status RECRUITING

Uniwersytecki Szpital Kliniczny Nr W Lublinie

Lublin, , Poland

Site Status RECRUITING

Aidport Sp Z O O

Skorzewo, , Poland

Site Status RECRUITING

Auxilio Mutuo Cancer Center

San Juan, , Puerto Rico

Site Status RECRUITING

Pusan National University Hospital

Seogu, Busan Gwang'yeogsi, South Korea

Site Status RECRUITING

Seoul National University Bundang Hospital

BundangGu SeongnamSi, Gyeonggi-do, South Korea

Site Status RECRUITING

Samsung Medical Center

GangnamGu, Seoul Teugbyeolsi, South Korea

Site Status RECRUITING

The Catholic University of Korea, Seoul St Marys Hospital

SeochoGu, Seoul Teugbyeolsi, South Korea

Site Status RECRUITING

Severance Hospital Yonsei University Health System

SeodaemunGu, Seoul Teugbyeolsi, South Korea

Site Status RECRUITING

Seoul National University Hospital

Seoul, Seoul Teugbyeolsi, South Korea

Site Status RECRUITING

Asan Medical Center

SongpaGu, Seoul Teugbyeolsi, South Korea

Site Status RECRUITING

The Catholic University of Korea, Yeouido St Marys Hospital

Yeongdeungpo-gu, Seoul Teugbyeolsi, South Korea

Site Status RECRUITING

Ico H Duran I Reynals

Barcelona, , Spain

Site Status RECRUITING

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario Fundacion Jimenez Diaz

Madrid, , Spain

Site Status RECRUITING

H Puerta de Hierro Majadahonda

Majadahonda, , Spain

Site Status RECRUITING

Antalya Memorial Hospital

Dokuma, , Turkey (Türkiye)

Site Status RECRUITING

Kocaeli Universitesi Tip Fakultesi

Kocaeli, , Turkey (Türkiye)

Site Status RECRUITING

The Royal Bournemouth and Christchurch Hospitals Nhs Foundation

Bournemouth, , United Kingdom

Site Status RECRUITING

Beatson West of Scotland Cancer Centre

Glasgow, , United Kingdom

Site Status RECRUITING

Churchill Hospital Oxford University Hospital Nhs Trust

Headington, , United Kingdom

Site Status RECRUITING

University College Hospital

London, , United Kingdom

Site Status RECRUITING

Clatterbridge Cancer Centre

Metropolitan Borough of Wirral, , United Kingdom

Site Status RECRUITING

Derriford Hospital

Plymouth, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Brazil China France Germany Italy Japan New Zealand Poland Puerto Rico South Korea Spain Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Study Director

Role: CONTACT

Phone: 1.877.828.5568

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-515593-27-00

Identifier Type: CTIS

Identifier Source: secondary_id

CTR20250207

Identifier Type: REGISTRY

Identifier Source: secondary_id

BGB-11417-302

Identifier Type: -

Identifier Source: org_study_id